Application of PI3K or AKT inhibitors might deplete therapy resistant low expressing FOXO3A breast cancer cells in addition to breast cancer cells with activated PI3K/AKT/β-catenin [35] within a heterogeneous breast cancer cell population. This evidence concerns the gene AKT1 and breast cancer.